Does the Pretransplant Use of Statins in Recipients Have a Role in the Incidence of Primary Graft Dysfunction after Lung Transplantation? R-ESTAcitos: Multicenter Clinical Study

Primary graft dysfunction (PGD) is the main cause of mortality during the first month and the second one within the first year after lung transplant (LT) Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, have shown to have immunomodulatory and antiinflamatory effects unrelated to their cholesterol-lowering function. We hypothesized that recipient's preoperative statin therapy is associated with decreased incidence of PGD after LT.

Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: I. Bello, A. Sandiumenge, E. Coll, M. de la Torre, V. Mora, S. Crowley, J. P érez, F. Mosteiro, M. Pérez, Á. Ballesteros, C. Álvarez, J. Escrivà, J. Galán, A. Gómez, J. Sacanell, L. Sánchez, C. Berastegui, C. Mazo, M. Deu, A. Jauregui Tags: (383) Source Type: research